Business
Directorate Changes
Directorate Changes.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n\n \n\nArecor Therapeutics plc\n(\"Arecor\" or the \"Company\")\n \nExecutive and Non-Executive Board Changes\n- Simon Ormiston, former partner PwC appointed as NED & Chair of Audit and Risk Committee, taking over from Christine Soden\n- David Ellam, CFO elevated to an Executive Director on the Board\n \nCambridge, UK, 29 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, announces changes to the Board, including the appointment of a new Chair to the Audit & Risk Committee and the elevation of the CFO to Executive Director, with immediate effect.\nSimon Ormiston\nSimon is a Chartered Accountant and former audit partner at PwC. He has been appointed as a Non-Executive Director and the new Chair of the Audit & Risk Committee. In his c.30 years at PwC, of which more than half was spent as a partner, he specialised in financial accounting, reporting, auditing and risk management, focusing on the growth companies in the life sciences and technology sectors. He has a strong track record of assisting both private and public companies to achieve their strategic ambitions, preparing for IPO and M&A transactions and strengthening governance. His clients included those listed on AIM and the main market of the London Stock Exchange, as well as on other European and US exchanges.\nSimon is taking on the Chair of the Audit & Risk Committee from Christine Soden, who has decided to step down from the Board and the Chair role, as part of the board succession plan.\nDavid Ellam, CFO\nDavid was appointed as interim CFO in November 2024, became full time CFO in February 2025 and is now moving onto the Board as Executive Director. He is an experienced finance professional and chartered accountant, with over two decades of experience in the life sciences industry. He has held CFO roles at numerous healthcare companies including Juvenescence, Silence Therapeutics, and more recently, Sixfold Bioscience. He qualified as a Chartered Accountant at PwC.\nAndy Richards, Chairman of Arecor said:\n\"I am pleased to welcome the two new members of the Arecor Board, Simon and David, and give a big thank you to Christine Soden. Chistine joined the ...